Cancer Immunotherapy, Metabolic Oncology, and What a Ketogenic Diet Has to Do With Cancer Drugs

New Frontiers in Cancer: Immunotherapy, Metabolic Oncology, and What a Ketogenic Diet Has to Do With Cancer Drugs

Cancer research is moving faster than it ever has. In the past two decades, the field has been transformed by two developments that would have seemed implausible to earlier generations of oncologists: the rise of immunotherapy, which harnesses the body’s own immune system to fight cancer, and the emergence of metabolic oncology, which explores how the body’s nutritional and metabolic state shapes cancer’s behavior and its response to treatment.

These are not fringe ideas. They are increasingly mainstream, evidence-supported directions that are reshaping how we think about cancer, and how we think about prevention.

As a performance and optimization specialist, I want to share what I find most compelling about these developments and what they mean for how we approach health and longevity at RMRM.

1. Immunotherapy: How the Science Actually Works

For most of medical history, the relationship between the immune system and cancer was poorly understood. We knew that people with severely compromised immune systems, such as patients with HIV, developed certain cancers at dramatically elevated rates. But these were mostly virus-associated cancers. Patients with HIV did not seem to develop lung cancer or pancreatic cancer at substantially higher rates, which suggested that the immune system’s role in controlling these common solid tumors was limited or unclear.

What researchers eventually discovered was that the story was one layer deeper. Cancer cells, particularly in solid tumors, had evolved mechanisms to evade immune detection. They were not simply invisible to the immune system. They were actively suppressing it. Specific proteins on the surface of cancer cells were sending signals to immune cells that said, in effect, stand down, I am not a threat.

The identification of these specific suppression pathways, particularly the CTLA-4 and PD-1 checkpoints, was the breakthrough that earned the 2018 Nobel Prize in Physiology or Medicine. By developing drugs that block these checkpoint signals, researchers essentially released the immune system’s brakes, allowing T cells to recognize and attack cancer cells that had previously evaded detection.

What makes immunotherapy particularly significant is not just that it works, but that when it works, the responses can be durable in a way that chemotherapy rarely achieves. In some patients, particularly those with melanoma and certain types of lung cancer, remissions have lasted years or even decades. This is because an immunologic response is not just killing cancer cells, it is educating the immune system to recognize and continue fighting the cancer over time.

Not all cancers respond equally. Understanding why some tumors are highly susceptible to checkpoint blockade while others are not is one of the most active areas of current research. But the principle has been firmly established: the immune system is a powerful and learnable weapon against cancer, and we are only beginning to understand how to wield it.

2. Metabolic Oncology: When Diet Affects How Cancer Drugs Work

Here is where the story takes a turn that I find particularly compelling for my patients, because it connects directly to the lifestyle and nutritional choices they make every day.

Cancer cells, as I have written about in previous articles, are dependent on fermentable fuels, primarily glucose and glutamine. One of the promising drug classes that has emerged from cancer metabolism research is PI3-kinase inhibitors, a family of drugs that target a fundamental signaling pathway involved in how cancer cells respond to insulin and glucose. These drugs showed early promise in clinical trials but encountered a confounding problem: many patients on them developed elevated blood sugar and elevated insulin levels, essentially a drug-induced pre-diabetic state.

The question that emerged was whether this metabolic side effect, hyperinsulinemia, was contributing to drug resistance. The hypothesis was elegant and concerning: the drug was blocking one of cancer’s key survival signals, but in doing so, it was triggering the body to produce more insulin. That insulin was then providing cancer cells with an alternative growth signal, effectively undermining the drug’s effect. The drug was being sabotaged by the body’s own metabolic response.

Research examining this hypothesis in animal models found exactly that. And then the critical next step: when animals were placed on a ketogenic diet, which dramatically reduces insulin levels, the resistance was blocked. The combination of the drug and the diet worked far more effectively than the drug alone. The drug silenced one signal, and the diet prevented the compensatory insulin surge that the cancer was exploiting.

Several important caveats apply here. This research was conducted in animal models, and human trials are underway. The effect was specific to the combination of the drug and the dietary intervention. The ketogenic diet alone did not show consistent anticancer effects across all cancer types, and in some cancer models it actually appeared to accelerate tumor growth. This is not a prescription for treating cancer with diet alone. It is an emerging and genuinely exciting area of science that suggests dietary interventions may be able to enhance the effectiveness of specific cancer drugs by modifying the metabolic environment in which those drugs operate.

The broader principle, that the metabolic state of the body shapes how cancer behaves and how it responds to treatment, is one of the most important ideas in modern oncology. And it is one that connects directly to the lifestyle optimization work we do at RMRM.

3. Obesity, Insulin, and Cancer Risk

One of the most significant epidemiological developments in cancer research over the past two decades is the growing recognition that obesity, or more precisely the metabolic phenotypes associated with it, is now the second leading preventable cause of cancer after tobacco.

But obesity itself is a crude phenotype. What drives cancer risk is not simply body weight but the specific metabolic consequences of excess adiposity: chronically elevated insulin, chronic low-grade inflammation, elevated inflammatory cytokines, and impaired immune function. Each of these mechanisms has plausible and documented connections to cancer development and progression.

This matters enormously for prevention. If hyperinsulinemia is a meaningful driver of cancer risk, then any intervention that lowers insulin, through diet, exercise, sleep optimization, stress management, and body composition improvement, is also potentially a cancer risk reduction strategy. These are exactly the interventions that we build personalized protocols around at RMRM.

Explore our diagnostics and therapies, annual membership, and our approach to see how we integrate these principles into a comprehensive longevity strategy.

4. The Three Laws of Medicine: A Framework for Thinking Clearly

One of the most valuable frameworks I have encountered for thinking clearly about medicine and health comes not from a laboratory but from a way of approaching uncertainty. There are three principles that I find myself returning to constantly in clinical practice.

These principles apply far beyond oncology. They are a framework for thinking clearly about any complex question, in medicine and in life.

5. What This Means for Prevention

The thread connecting immunotherapy, metabolic oncology, and the epidemiology of obesity-related cancer risk is a single, powerful idea: cancer is not simply a matter of bad luck or bad genes. It is a disease that emerges from a biological environment, and that environment is substantially shaped by lifestyle.

Maintaining metabolic health, controlling insulin and blood glucose, building and preserving lean mass, managing inflammation, protecting sleep, and reducing chronic stress are not just strategies for preventing cardiovascular disease or metabolic syndrome. They are strategies for creating a biological environment that is hostile to cancer development and that supports the immune surveillance that keeps pre-cancerous cells from progressing.

This is the integrated view of prevention that drives everything we do at RMRM. Not treating disease after it emerges, but building the physiological conditions that make disease less likely to emerge in the first place.

Book an appointment with our team to begin building your personalized prevention and longevity strategy. Explore our therapies, including hyperbaric oxygen therapy, peptide therapy, IV infusion therapy, and hormone therapy. And learn about our annual membership for ongoing, comprehensive optimization.

Frequently Asked Questions By Patients

Patient Success Stories

These patient success stories reflect our commitment to treating the root biological causes of knee pain, rather than just masking symptoms. Our mission is to help you restore function, stay active, and age stronger, so you can move better and live better every day.